No Data
No Data
Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio
Biogen Downgraded to Hold by Jefferies, Ocrevus Royalties Cited
Reported Sunday, Roche's Genentech Showcases Polivy's Transformative Impact On Frontline DLBCL Treatment: Five-Year POLARIX Trial Results Presented At ASH 2024
Kepler Capital Sticks to Their Buy Rating for Roche Holding AG (RHHVF)
FDA Accepts Roche's Columvi SBLA for Expanded Use in Lymphoma
Roche (RHHBY.US) CD20/CD3 bispecific antibody new indication application accepted by the FDA.
Roche (RHHBY.US) announced that the FDA has accepted the supplemental biological product license application (sBLA) for glofitamab.